2129
Bempedoic Acid a Small Molecule Drug Process and Synthesis, Innovation And Or Advantages, Development Status And Or Regulatory Status.pdf
Bempedoic Acid a Small Molecule Drug Process and Synthesis, Innovation And /Or Advantages, Development Status And /Or Regulatory Status
<p>Low Density Lipoprotein Cholesterol</p><p> </p><p><br />Abstract<br />Bempedoic acid (ETC-1002), a small molecule drug, promotes low density lipoprotein (LDL) receptor mediated clearance<br />of LDL-cholesterol (LDL-C) by inhibition of adenosine triphosphate citrate lyase (ACL), a mechanism complementary to those<br />of existing lipid-modifying therapies. Bempedoic acid is a pro-drug activated specifically within the liver where it inhibits ACL,<br />a regulatory checkpoint within the cholesterol biosynthesis pathway. By inhibiting ACL, bempedoic acid reduces cholesterol<br />synthesis in liver cells and triggers compensatory LDL receptor upregulation. Inhibiting ACL with bempedoic acid complements<br />other mechanisms targeted by current therapies, resulting in additional lowering of LDL-C, without leading to increases in adverse<br />events (AEs).b In the phase III clinical trials (NCT02666664, NCT02991118) of patients with high cardiovascular risk and elevated<br />LDL-C not adequately controlled by their current therapy, patients are given a daily dose of 180 mg bempedoic acid as an oral tablet,<br />whilst remaining on ongoing lipid-modifying therapy. The present paper describes the process and synthesis, innovation and /or<br />advantages, development status and /or regulatory status of Bempedoic acid.<br /> </p>
Adobe PDF
Drkrishnasarmapathy
application/pdf
http://www.myexperiment.org/files/2129/download/Bempedoic Acid a Small Molecule Drug Process and Synthesis, Innovation And Or Advantages, Development Status And Or Regulatory Status.pdf
2019-07-23 07:04:13 UTC
by-sa